BELITE BIO, INC Annual Report - How They Did This Year

I’m putting together a plain-English guide to help you understand how Belite Bio performed this year. My goal is to turn complex filing information into something you can use to decide if this company fits your investment goals.

1. What does this company do?

Belite Bio is a clinical-stage biotech company developing treatments for degenerative eye diseases. Their main focus is tinlarebant (LBS-008), an oral medication for Stargardt disease—a rare condition causing vision loss—and geographic atrophy linked to macular degeneration. Because they are still testing their drugs, they have earned $0 in sales. Their value is entirely speculative, based on the success of their Phase 3 clinical trials and potential future approval from regulators.

2. Financial health: The "Burn" Phase

Belite Bio is currently spending heavily to fund its research. For the year ending December 31, 2023, the company lost about $36.2 million. This included $26.8 million for research and $9.4 million for general business costs. By the end of 2023, they held about $45.6 million in cash and short-term investments. With a monthly spending rate of roughly $3 million, they will need to raise more money to keep operating until their trials are finished.

3. Major wins and challenges

The company raises money primarily by selling new shares. In 2023, they raised about $25 million this way. While this funded their Phase 3 trials, it also caused "dilution." This means the company issued more shares, which reduced the ownership percentage of existing shareholders. The progress of their research is the primary driver of value, but the constant need for cash remains a significant hurdle.

4. Key risks: What could go wrong?

It is important to be clear about the risks. Since they have no products for sale, their future depends entirely on tinlarebant.

• The "All-in" Risk: The company has no other drugs in its pipeline. If their trials fail or the FDA finds safety issues, they have no backup plan. This would likely cause the stock price to drop significantly.
• Dependency on Partners: Belite relies on outside companies to run their trials and manufacture their drugs. If these partners face supply issues or performance failures, it could delay the company’s progress.
• Ownership Influence: Lin Bioscience, Inc. owns a controlling stake. This means minority shareholders have little say in how the company is run.
• Intellectual Property: The company’s value relies on its patents, which begin expiring in 2034. If they cannot defend these patents, their competitive advantage will disappear.

5. Future outlook

The company is playing a long game, running global trials to satisfy regulators in the U.S., Europe, and Asia. Their immediate goal is to reach key milestones in their Phase 3 trials.

Bottom line: This is a high-risk, high-reward investment. You are not buying a profitable business; you are betting on the success of scientific trials. If you invest, remember that they are essentially a research project that needs constant funding. Given their $36 million annual loss and limited cash, expect them to issue more shares or take on debt within the next 12–18 months. Before buying, ask yourself if you are comfortable with the volatility that comes with a company that has no revenue and a single-drug focus.